Start here if you're new
what it is
Lyell is a biotech trying to sell CAR T cancer treatments and the factory that makes them.
how it gets paid
Last year Lyell Immunopharma made $36K in revenue. CAR T research programs was the main engine at $14K, or 39% of sales.
why growth slowed
Revenue fell 41.0% last year. Revenue was $30K, and that is tiny next to a $495M market cap.
what just happened
The latest quarter brought in $30K of revenue and -$8.38 EPS.
At a glance
C++ balance sheet — some cracks in the foundation
-$19.60 fy2024 eps est
$0M fy2024 rev est
n/a operating margin
1.2 beta
xvary composite: 45/100 — below average
What they do
Lyell is a biotech trying to sell CAR T cancer treatments and the factory that makes them.
Lyell has 300 employees, and the story is built on 1,200 CAR T doses of capacity at full buildout. That is the weird part: you are paying for future medicine, not current sales. Leaving is painful because the company is trying to own both the therapy and the factory.
How they make money
$36K
annual revenue · their business grew -41.0% last year
CAR T research programs
$14K
manufacturing services
$10K
collaboration and licensing
$8K
other revenue
$4K
The products that matter
lead clinical program
LYL273
primary equity driver
This is the program doing the real storytelling. With just $36,000 of company-wide revenue, your upside or downside is still tied more to LYL273 readouts than to any commercial metric.
main catalyst
collaboration revenue stream
Collaboration revenue
$10K
It contributed $10K of the total $36,000 revenue base. That is too small to support the valuation, so you should treat it as accounting residue, not proof of traction.
too small to matter
everything outside the lead asset
Other revenue and pipeline optionality
$26K
The remaining $26K of revenue tells you the same thing as the $10K line: there is no diversified business underneath yet. If management wants the market to believe this is more than one asset, future data have to prove it.
second question
Key numbers
$36K
annual revenue
That is the whole business line next to a $495M market cap.
$495M
market cap
You are paying almost half a billion dollars for a company with almost no sales.
$44M
long-term debt
Debt matters when revenue is $36K, because lenders get paid before equity holders do.
1,200
dose capacity
The manufacturing center can make 1,200 CAR T doses at full capacity, so execution is the entire game.
Financial health
C++
strength
- balance sheet grade C++ — below average — limited financial resources
- risk rank 4 — safer than 20% of stocks
- price stability 5 / 100
- long-term debt $44M (8% of capital)
C++ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for LYEL right now.
source: institutional data · return history unavailable
What just happened
missed estimates
The latest quarter brought in $30K of revenue and -$8.38 EPS.
Revenue was $30K, up 100% vs. prior year. That sounds better until you remember the business still barely sells anything.
$30K
revenue
-$8.38
eps
n/a
n/a
revenue
Revenue was $30K, and that is tiny next to a $495M market cap.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the top risk here is LYL273 failing to produce investable clinical data. With only $36,000 of revenue, there is no mature business underneath to absorb that kind of disappointment.
med
LYL273 disappoints
This is the main stock-specific risk. If the lead program fails to show the efficacy or safety the market wants, the thesis breaks because the company does not have product revenue to fall back on.
Impact: the valuation can reprice fast because most of the current ~$495M market value rests on future hopes rather than present cash generation.
med
cash burn forces new financing
A C++ balance sheet grade and $44M of long-term debt are manageable only if timelines hold. If trials run longer or cost more, new capital becomes part of the story again.
Impact: dilution is not a side issue for pre-commercial biotech. It changes what each existing share is worth.
med
the platform stays a slide, not a franchise
Management can talk about pipeline breadth, but the current numbers do not prove it. With $36,000 of revenue, investors still need evidence that value exists beyond one lead asset.
Impact: even decent data from one program may not earn a premium multiple if the rest of the pipeline fails to look repeatable.
If the lead program slips and financing needs rise at the same time, the story changes from clinical patience to balance-sheet stress. That is the combination to watch.
source: institutional data · regulatory filings · risk analysis
Pay attention to
trend
LYL273 is still the whole movie
With $36,000 of revenue and no meaningful sales, the stock still trades more on lead-program belief than on business execution. That has not changed.
calendar
next company update
Use the next update to judge timing discipline. You want clearer clinical milestones and cleaner financing language, not more patience sold as progress.
risk
balance-sheet pressure
C++ balance sheet grade and $44M of long-term debt mean runway matters. If costs rise before data improve, your bargaining position as a shareholder gets worse.
metric
real business traction
Right now the only revenue base is $36,000. Until that changes, revenue is a proof-of-absence metric: it tells you commercialization is still far away.
Analyst rankings
short-term outlook
mixed
target data is thin here. in human-speak: the street does not have a clean consensus because the thesis still depends on clinical proof.
risk profile
volatile
A 1.2 beta and 5 / 100 price stability tell you this will not trade like a steady compounder. Expect sharper moves around program updates.
chart momentum
catalyst-led
This stock trades on events more than on smooth trend lines. If you are looking for technical serenity, this is the wrong aisle.
earnings predictability
40 / 100
Predictability is low because there is no mature earnings base. One financing move or trial timing shift can change the near-term picture fast.
source: institutional data
Institutional activity
institutional ownership data for LYEL is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$28
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive